Chargement en cours...
Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients
Addition of brentuximab vedotin, a CD30-targeted antibody–drug conjugate, and the programmed death 1 (PD-1) inhibitors nivolumab and pembrolizumab to the armamentarium for transplant-ineligible relapsed/refractory classical Hodgkin lymphoma has resulted in improved outcomes, including the potential...
Enregistré dans:
| Publié dans: | Blood |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6536701/ https://ncbi.nlm.nih.gov/pubmed/29500171 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-772681 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|